Compare OGEN & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | VCIG |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | 2010 | 2022 |
| Metric | OGEN | VCIG |
|---|---|---|
| Price | $0.60 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 242.8K | ★ 338.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.20 |
| 52 Week High | $9.16 | $23.40 |
| Indicator | OGEN | VCIG |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 41.91 |
| Support Level | N/A | $0.94 |
| Resistance Level | $1.02 | $1.82 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 29.10 | 13.97 |
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.